Saratov JOURNAL of Medical and Scientific Research

Modern issue on the role of microorganisms in the induction and the development of atherosclerosis

Year: 2016, volume 12 Issue: №2 Pages: 113-117
Heading: Macro- and Micromorphology Article type: Review
Authors: Kupryushin AS, Chudaeva DG, Fedorova MG, Latynova IV, Vishnyakova ZhS, Kuprushyna NV, Efimov AA.
Organization: Penza State University

More than 70 literature sources are presented and analyzed in the work. Data sources are devoted to the connection between infection and development of atherosclerotic changes. It has been found out that the infection and the presence of pathogenic microorganisms influence the progression of atherosclerosis.

1. World Health Organization. The World Health Report 2014. URL:>gho/publications/world_health...2014/en/
2. Leinonen M, Saikku P. Infections and atherosclerosis. Scandinavian Cardiovascular Journal 2000; 34 (1): 12-20
3. Ono A, Freed E. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 13925-13930
4. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: A dangerous liaison in Alzheimer's disease and other disorders. Progress in Lipid Research 2005; 34: 123-131
5. Sun X, Whittaker GR. Role for influenza virus envelope cholesterol in virus entry and infection. Journal of Virology 2003; 77: 12543-12551
6. Beer C, Pedersen L, Wrth M. Amphotropic murine leukaemia virus envelope protein is associated with cholesterol rich microdomains. Journal of Virology 2005; 2: 36-45
7. Chung CS, Huang CY, Chang W. Vaccinia virus penetration requires cholesterol and results in specific viral envelope proteins associated with lipid rafts. Journal of Virology 2005; 79: 1623-1634. 8. Katzman RB, Longnecker R. Cholesterol dependent infection of Burkitt's lymphoma cellines by Epstein — Barr virus. J Gen Virol 2003; 84: 2987-2992
9. Empig CJ, Goldsmith MA. Association of the caveola vesicular system with cellular entry by filoviruses. J Virol 2002; 76: 5266-5270
10. Reyes Del Valle J, Chavez Salinas S, Medina F, et al. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol 2005; 79: 4557-4567
11. Manie SN, Debreyne S, Vincent S, et al. Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly. J Virol 2000; 74: 305-311
12. Nakayama M, Hisatsune J, Yamasaki E, et al. Clustering of Helicobacter pylori VacA in lipid rafts, mediated by its receptor, receptor like protein tyrosine phosphatase beta, is required for intoxication in AZ 521 cells. Infect Immun 2006; 74: 6571-6580
13. Risselada HJ, Marrink SJ. The molecular face of lipid rafts in model membranes. Proc Natl Acad Sci USA 2008;105: 17367-17372
14. Maziere JC, Landureau JC, Giral P, et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol poor medium. Biomed Pharmacother 1994; 48: 63-67
15. Campbell SM, Crowe SM, Мак J. Virion associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. Aids 2002; 16: 2253-2261
16. Guyader M, Kiyokawa E, Abrami L, et al. Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 2002; 76: 10356-10364
17. Sainz BJ, LaMarca HL, Garry RF, et al. Synergistic inhibition of human cytomegalovirus replication by interferon-alpha, — beta and interferon-gamma. J Virol 2005; 2: 14
18. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Atherogene investigators: impact of infectious burden on extent and longterm prognosis of atherosclerosis. Circulation 2002; 105: 15-21
19. Ibrahim Al, Obeid MT, Jouma MJ, et al. Detection of herpes simplex virus, cytomegalovirus and Epstein — Barr virus DNA in atherosclerotic plaques andin unaffected bypass grafts. J ClinVirol 2005; 32(1): 29-32
20. Schlitt A, Blankenberg S, Weise K, et al. Herpesvirus DNA (Epstein — Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease. Acta Cardiol 2005; 60 (6): 605-610
21. Shi Y, Tokunaga O. Herpesvirus (HSV1, EBV and CMV) infections in atherosclerotic compared with non-atherosclerotic aortic tissue. Pathol Int2002; 52 (1): 31-39
22. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1977; 70: 1753-1756
23. Gandzha I.M. Mechanism of influence of a viral infection on defeat of vessels and myocardium. Medichnij Vsesvit 2001; 1: 21
24. Milnich J, Adam E, De Bakey M. Cytomegalovirus and atherosclerosis. Arch Immunol Ther Exp (Warsz) 1996; 44 (5-6): 297-302
25. Fabricant CG, Fabricant J, Minick CR, et al. Atheroarteriosclerosis induced by infection with herpesvirus. Fed Proc 1983; 42 (8): 2476
26. Hajjar DP, Fabricant CG, Minick CR, et al. Virus-induced atherosclerosis. Amer J Pathol 1986; 122 (1): 62
27. Surnin S.A., Sobenin I.A., Karagodin V.P., et al. The inducing role of viruses sharp respiratory virus infections in a progression of atherosclerotic process. Problems and prospects of modern science 2011; 3 (1): 57-58
28. Muhlestein JB. Chronic infection and coronary artery disease. Med Clin North Am 2000; 84 (1): 123-148
29. Peremot S.D., Celujko V.I., Smeljanskaja M.V., et al. Influence of representatives of Herpesviridae family on the course of coronary heart disease. Ukrainian cardiological journal 2000; 3: 30-33
30. Emingil G, Buduneli Е, Aliyev A, et al. Association between periodontal disease and acute myocardial infarction. J Periodontol 2000; 71 (12): 1882-1886
31. Higgins JP, Higgins JA, Higgins PM, et al. Chlamydia pneumoniae and coronary artery disease: legitimized linkages. Expert Rev Cardiovasc Ther 2003; 1 (3):367-384
32. Kajander EO. Nanobacteriapropagating calcifying nanoparticles. Lett Appl Microbiol 2006; 42 (6): 549-552
33. Kalayoglu MV, Libby P, Byrne Gl. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288 (21): 2724-2731
34. Muhlestein JB. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 2003; 14 (6): 605-614
35. Rauscher FM, Goldschmidt Clermont PJ, Davis BH, et al. Aging, Progenitor Cell Exhaustion, and Atherosclerosis. Circulation 2003; 108 (4):457-463
36. Shhupakova A.N. Communication of a virus of simple herpes with peripheral atherosclerosis. Achievements of medical science of Belarus 2003; 8: 117-118
37. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. Engl J Med 2006; 335: 624-630
38. Gurevich ВС. Role of viruses of flu in progressing of atherosclerosis. In: Kardiologija — XXI vek: Materialy konf. SPb., 2001; p. 212-213
39. Filippov А.Е. Total pathogenic loading and its connection with progressing of coronary heart disease. Bulletin of the St. Petersburg medical academy n.a. Mechnikov 2004; 3: 22-27
40. Matsuura Е, Kobayashi К, Tabuchi М, et al. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006; 45 (6): 466-486
41. Guan XR, Jiang LX, Ma XH, et al. Respiratory Syncytial Virus Infection and Risk of Acute Myocardial Infarction Am J Med Sci 2010; Aug 31 [Epub ahead of print]
42. Koskela R, Mutanen P, Sorsa J, et al. Respiratory disease and cardiovascular morbidity. Occup Environ Med 2005; 62 (9): 650-655
43. Kreutz R, Bliden K, Tantry U, et al. Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. Journal of Thrombosis and Haemostasis 2005;3:2108-2109
44. Aburawi E, Liuba P, PesonenE, et al. Acute Respiratory Viral Infections Aggravate Arterial Endothelial Dysfunction in Children With Type 1 Diabetes. Diabetes Care 2004; 27 (4): 2733-2735
45. Krylov A.A., Stolov S.V., Lineckaja N.E. Role of inflammatory and infectious factors in development of atherosclerosis. Clinical medicine 1999; 11: 60-62
46. Sumarokov А.В., Ljakishev V.N. The chlamydial infection caused by Chlamidia pneumonia, and atherosclerosis. Clinical medicine 1999; 7: 4-10
47. Titov V.N. Cardial questions of pathogenesis of atherosclerosis: present and prospects. Therapeutic archive 2001; 73 (2): 78-82
48. Klimov I.A, Cepkov G.A., Poznjak А.А. Atherosclerosis of coronary vessels and clamidiosis. Regionar blood circulation and microcirculation 2002; (1): 53-56
49. Linnanmiaki Е., Leinonen М., Mattila К. Chlamydia pneumoniae-specifie circulation immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130— 1134. 50. Saikku P., Leinonem M, Mattila K, et al. Chronic Chlamidia pneumonia infection as the risk factor for coronary heart disease in Helsinki heart study. Ann Intern Med 1992; 116 (4): 273-278
51. Blasi F, Denil F, Ezba M, et al. Detection of Chlamidia pneumoniae but not Helicobacter pylory in atherosclerotic plagues of aortic aneurisms. J Clin Microbiol 1996; 34(11):27-69
52. Kowalski M, Konturek PC, Pieniazek P, et al. Prevalence of Helicobacter pylori infection in coronary lumen reduction after percutaneous coronary angioplasty. Dig Liver Dis 2001 Apr; 33 (3): 222-229
53. Osawa H, Kawakami M, Fujii M, et al. Helicobacter pylori infection and coronary heart disease in Japanese patients. Cardiology 2001; 95(1): 14-19
54. Konturek PC, Kowalsky M, Nasseri R, et al. Detection of Helicobacter pylori specific DNA in human coronary artery atherosclerotic plaques. In: XlVth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Strasbourg, 6-8 September, 2001
55. Rudyk JuS, Smeljanskaja MV, Peremot SD, et al. Communication of Helicobacter pylori with coronary heart disease. Ukrainian chemotherapeutic journal 2000; 3: 43-48
56. Farsak В, Yildirir A, Akyon Y, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. Journal of Clinical Microbiology 2000 Dec; 38 (12): 4408-4411
57. Pellicano R, Oliaro E, Gandolfo N, et al. Ischaemic cardiovascular disease and Helicobacter pylori: Where is the link. J of Cardiovascular Surgery (Torino) 2000 Dec; 41 (6): 829-833
58. Anderson JL, Carlquist JF, Muhlestein JB, et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998 Jul; 32 (1): 35-41
59. Laurila A, Bloigu A, Nayha S, et al. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999 Jan; 142 (1): 207-210
60. Galante A, Pietroiusti A, Carta S, et al. Infection with Helicobacter pylori and leukocyte response in patients with myocardial infarction. Eur J Clin Microbiol Infect Dis 2000 Apr; 19 (4): 298-300
61. Gassbarrini A, Cremonini F, Armuzzi A, et al. The role of Helicobacter pylori in cardiovascular and cerebrovascular diseases. J Physiol Pharmacol 1999 Dec; 50 (5): 735-742
62. Famularo G, Trinchieri V, Santini G, De Simone С Infections, atherosclerosis, and coronary heart disease. Ann Ital Med Int Jun 2000 Apr; 15(2): 144-155
63. Grabczewska Z, Nartowicz E. Infections with Chlamidia pneumoniae, Helicobacter pylori or cytomegalovirus and atherosclerosis. Przegl Lek 1999; 56 (9): 584-587
64. Zellner C, Chou TM. Antibiotic prophylaxis and treatment of cardiovascular disease.Circulation 1999; 99 (14): 1922-1923
65. Stone A. Does Helicobacter pylori cause heartdisease. In: 8th United European Gastroenterology Week 25-30 November 2000, Brussels, Belgium
66. Isakov V.A., Kudrjavceva L.V. Azitromitsin (Sumamed) is a new component of anti-helicobacter therapy. Clinical pharmacology and therapy 2000; 9 (1): 22-24
67. Hishiki S, Shiwa Т, Yokoyama Т, et al. Change of cardiovascular risk factors after eradication therapy of Helicobacter pylori. Nippon Shokakibyo Gakkai Zasshi 2001 Jul; 98 (7): 814-821
68. Paoluzi P, Consolazio A, Borgia Mc, et al. Increased thrombin generation in patients with chronic gastritis and Helicobacter pylori infection. In: 8th United European Gastroenterology Week 25-30 November 2000, Brussels, Belgium
69. Oderda G, Chiorboli E, Haitink O, et al. Plasma fibrinogen decreases after eradication in children with Helicobacter pylori gastritis. In: Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Septemer 12-14, 1997, Lisbon, Portugal
70. Wang Z, Klipfell E, Bennett B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 2011;472:57-63
71. Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010 Oct; 105 (10): 2218-2227
72. Wang Z, Klipfell E., Bennett BJ.,etal. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63. n7341/full/nature09922.html. (06 April 2011)
73. Tang W, Wang Z, Levison B, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-1584
74. Jernberg C, Lofmark S, Edlund C, et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010; 156: 3216-3223
75. Tolstikova T.V., Bregel' L.V., Kiklevich V.T., et al. Koronariita at children. Siberian medical journal 2009; 2: 110-112.

2016_02_113-117.pdf264.99 KB

No votes yet